 |
Wuhan Nutra Biotechnology Co., Ltd.ISRIB ,Cosmetic Peptide, Tideglusib ,Way316606,Nootropics |
    
   
|
|||
Contact Us
E-mail: catherine@nutrabiotechchem.com
Obeticholic Acid
Product Description:
Product Name: Obeticholic Acid
Synonyms: 6-Ethylchenodeoxycholic acid;6alpha-Ethyl-chenodeoxycholic acid;6-Ecdca;6-Ethyl-cdca;C15636;6-Ethylchenodeoxycholic acid(Obeticholic Acid);Obeticholic Acid;(3α,5β,6α,7α)-6-ethyl-3,7-dihydroxy-cholan-24-oic acid
CAS: 459789-99-2
MF: C26H44O4
MW: 420.63
Obeticholic acid (Obeticholic Acid), also known as 6-ethyl chenodeoxycholic acid, is a new derivative of chenodeoxycholic acid (CDCA) in the primary bile acid, and a natural ligand for the farneside derivatives X receptor ( FXR). Oberbetaine is an agonist for farnesol X receptor, inhibiting gene expression of cytochrome 7A1 (CYP7A1) by activating the farnesol X receptor. Because CYP7A1 is the rate-limiting enzyme for biosynthesis of cholic acid, it can inhibit cholic acid synthesis and is useful in the treatment of primary biliary cirrhosis and nonalcoholic fatty liver disease.
Oberbic acid is developed by the US Intercept Pharmaceutical Company, and it is the first drug in 20 years developed for the treatment of cholestatic liver disease.The study was applied to patients who did not adequately respond to or cannot tolerant the old standard treatment——ursodeoxycholic acid. In a phase III, placebo-controlled trial, oberbetate (OCA) increased the levels of two biomarkers associated with a reduced risk of liver transplantation. The composite endpoint of clinical studies is a decrease at least 15% in alkaline phosphatase activity and of a serum albuminase activity which is 1.67-fold lower than the normal upper limit, whereas in the normal range of bilirubin, alkaline phosphatase is a biomarker used to indicate the severity of liver disease.
Synonyms: 6-Ethylchenodeoxycholic acid;6alpha-Ethyl-chenodeoxycholic acid;6-Ecdca;6-Ethyl-cdca;C15636;6-Ethylchenodeoxycholic acid(Obeticholic Acid);Obeticholic Acid;(3α,5β,6α,7α)-6-ethyl-3,7-dihydroxy-cholan-24-oic acid
CAS: 459789-99-2
MF: C26H44O4
MW: 420.63
Obeticholic acid (Obeticholic Acid), also known as 6-ethyl chenodeoxycholic acid, is a new derivative of chenodeoxycholic acid (CDCA) in the primary bile acid, and a natural ligand for the farneside derivatives X receptor ( FXR). Oberbetaine is an agonist for farnesol X receptor, inhibiting gene expression of cytochrome 7A1 (CYP7A1) by activating the farnesol X receptor. Because CYP7A1 is the rate-limiting enzyme for biosynthesis of cholic acid, it can inhibit cholic acid synthesis and is useful in the treatment of primary biliary cirrhosis and nonalcoholic fatty liver disease.
Oberbic acid is developed by the US Intercept Pharmaceutical Company, and it is the first drug in 20 years developed for the treatment of cholestatic liver disease.The study was applied to patients who did not adequately respond to or cannot tolerant the old standard treatment——ursodeoxycholic acid. In a phase III, placebo-controlled trial, oberbetate (OCA) increased the levels of two biomarkers associated with a reduced risk of liver transplantation. The composite endpoint of clinical studies is a decrease at least 15% in alkaline phosphatase activity and of a serum albuminase activity which is 1.67-fold lower than the normal upper limit, whereas in the normal range of bilirubin, alkaline phosphatase is a biomarker used to indicate the severity of liver disease.
Links:
Copyright © Wuhan Nutra Biotechnology Co., Ltd. All right reserved
